Inclusion Criteria:

- Patients with ectocervical CIN1 or CIN2 as verified by local pathology (biopsy)
obtained within the last month

- Satisfactory colposcopy examination including:

- visibility of entire transformation zone including the squamocolumnar junction
and

- visibility of entire lesion margin

- Negative endocervical os by colposcopy

- Colposcopical visible lesion at visit 2, before treatment

- Patients with an average sized uterine cervix (approximately 27mm diameter) suitable
for application of the Klemcap

- Age 18 or above

- Written informed consent signed

Exclusion Criteria:

- Previous treatment of CIN or invasive disease

- Lesion(s) extending to the vaginal vault

- Atypical glandular cells (AGC) or adenocarcinoma in situ (AIS) on cytology, malignant
cells on cytology or histology or other suspicion of either micro-invasive or
invasive disease

- Suspicion of endocervical disease on colposcopy

- Current severe pelvic inflammatory disease, severe cervicitis, or other severe
gynaecological infection as per colposcopy and clinical examination

- Undiagnosed vaginal bleeding

- History of toxic shock syndrome

- Known or suspected porphyria

- Known allergy to hexaminolevulinate or similar compounds (e.g. methyl aminolevulinate
or aminolevulinic acid)

- Pregnancy, or intention to become pregnant during the study period

- Nursing

- Childbirth or miscarriage within six weeks of enrolment

- Use of heart pacemaker

- Participation in other clinical studies either concurrently or within the last 30
days

- Risk of poor protocol compliance. Patient participation should be considered with
respect to living far away from the hospital, plans for moving to another city/state,
frequent travelling, planning to become pregnant, drug abuse/alcoholic, difficult
working hours, family obligations, other illness (e.g. psychiatric), etc.

- Unwillingness to use adequate birth control (not abstinence) from screening until
last PDT

- Patient is the investigator or any sub-investigator, research assistant, pharmacist,
study coordinator, other staff or relative thereof directly involved in the conduct
of the protocol